Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAPLM for relapsed or refractory acute myeloid leukemia
ChiCTR2200063308Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of homoharringtonine, cytarabine and mitoxantrone-liposome in acute myeloid leukemia (AML), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Composite complete response rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
homoharringtoninecytarabinemitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200063308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063308.